Novel Antimicrobials and AMR Diagnostics 2019

News

Recida Therapeutics receives CARB-X funding

CARB-X funds US-company Recida Therapeutics to accelerate further development of the LpxC program to treat gram-negative superbugs.

CARB-X, a Boston University global partnership, is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to treat serious infections caused by Gram-negative bacteria. “The world urgently needs new classes of antibiotics and other life-saving products to prevent, diagnose, and treat deadly infections,” said Kevin Outterson, Executive Director of CARB-X and Boston University law professor. “Recida’s lead program inhibits LpxC, and would represent a new drug class against Gram-negative superbugs, if approved by the FDA.

The projects in the Powered by CARB-X portfolio are in early development, but if successful, they offer tremendous hope in the global fight against drug-resistant bacteria.” “We are very excited and most appreciative of the CARB-X award.” said James Ge, M.D., Ph.D., CEO of Recida. “Support from CARB-X significantly enhances our ability to take critical steps in the clinical development of this potentially life-saving antibiotic.”

The CARB-X award will help fund preparation of an Investigational New Drug (IND) application for RC-01 for submission to the US Food and Drug Administration (FDA), and if successful, a Phase 1 trial to be completed in 2019 and drug product manufacturing to support subsequent clinical trials. In preclinical testing, RC-01 has shown ability to inhibit LpxC, a key enzyme in Lipid A biosynthesis and essential component of the protective outer membrane of Gram-negative bacteria. LpxC is a validated target in Gram-negative bacteria, but there are no approved therapeutics targeting LpxC; past efforts have failed often as a result of poor drug-like properties or toxicity.

Recida was launched by Frazier Healthcare Partners to advance RC-01, recently licensed from FUJIFILM Toyama Chemical Co., to Phase 1 clinical trials. In testing, RC-01 has shown a promising safety profile and potent activity against Enterobacteriaceae and Pseudomonas aeruginosa. Enterobacteriaceae and P. aeruginosa are Gram-negative pathogens. They are among the world’s deadliest superbugs and often cause difficult-to-treat hospital-acquired infections. Patients whose care requires devices like ventilators, urinary catheters or intravenous catheters are most at risk for these types of infections.